MCID: MRK001
MIFTS: 58

Merkel Cell Carcinoma

Categories: Rare diseases, Skin diseases, Endocrine diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Merkel Cell Carcinoma

MalaCards integrated aliases for Merkel Cell Carcinoma:

Name: Merkel Cell Carcinoma 12 53 59 37 15 73
Trabecular Adenocarcinoma 12 6 73
Cutaneous Neuroendocrine Carcinoma 53 59
Carcinoma, Merkel Cell 53
Carcinoma Merkel Cell 55
Trabecular Carcinoma 12
Merkel Cell Cancer 53
Merkle Tumors 53
Mcc 59

Characteristics:

Orphanet epidemiological data:

59
cutaneous neuroendocrine carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe),1-9/100000 (Australia); Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:3965
NCIt 50 C4068
SNOMED-CT 68 29792007
Orphanet 59 ORPHA79140
UMLS via Orphanet 74 C0007129
ICD10 via Orphanet 34 C44.6 C44.7 C44.3
KEGG 37 H01555

Summaries for Merkel Cell Carcinoma

NIH Rare Diseases : 53 Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer. It usually develops as a single, painless, bump on sun-exposed skin. The bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. It may spread quickly to surrounding tissues, nearby lymph nodes, or more distant parts of the body. Factors associated with developing MCC include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the Merkel cell polyomavirus. This virus has been detected in about 80% of people with MCC. Treatment may include surgery, radiation therapy, and/or chemotherapy. Treatment options and prognosis depend on the location(s) and size of the cancer, whether it has just been diagnosed or has come back (recurred), and how deeply it has grown into the skin.

MalaCards based summary : Merkel Cell Carcinoma, also known as trabecular adenocarcinoma, is related to glomus tumor and spindle cell carcinoma. An important gene associated with Merkel Cell Carcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are NF-kappaB Signaling and Cytoskeletal Signaling. The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and brain, and related phenotypes are merkel cell skin cancer and cutaneous photosensitivity

Wikipedia : 76 Merkel-cell carcinoma (MCC) is a rare and highly aggressive skin cancer, which, in most cases, is caused... more...

Related Diseases for Merkel Cell Carcinoma

Diseases related to Merkel Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 glomus tumor 30.5 ENO2 SYP TP53
2 spindle cell carcinoma 30.3 ENO2 KRT7 MUC1 SYP
3 somatostatinoma 30.3 CHGA ENO2 SST
4 basal cell carcinoma 30.1 KRT20 KRT7 KRT8 TP53
5 paraganglioma 29.9 CHGA ENO2 SST SYP
6 pheochromocytoma 29.8 CHGA ENO2 SST SYP
7 neuroblastoma 29.3 ENO2 KIT NCAM1 SYP TP53
8 ewing sarcoma 28.9 CHGA ENO2 KIT NCAM1 SYP TP53
9 small cell carcinoma 28.4 CHGA ENO2 KIT KRT20 KRT7 NCAM1
10 neuroendocrine tumor 27.9 CHGA ENO2 KRT20 KRT7 NCAM1 NKX2-1
11 renal cell carcinoma, nonpapillary 27.7 CD274 KIT KRT20 KRT7 KRT8 MUC1
12 penile cancer 11.1
13 acinar cell cystadenocarcinoma 11.0 CHGA SYP
14 malignant sertoli cell tumor 11.0 ENO2 SYP
15 peritoneal serous adenocarcinoma 11.0 CHGA SYP
16 primary hepatic neuroendocrine carcinoma 11.0 CHGA SYP
17 embryoma 10.9 NKX2-1 SYP
18 mature teratoma of the ovary 10.9 ENO2 KRT20
19 intracranial primitive neuroectodermal tumor 10.9 CHGA ENO2
20 ovary neuroendocrine neoplasm 10.9 KRT7 SYP
21 cystic basal cell carcinoma 10.9 KRT20 KRT7
22 seminal vesicle adenocarcinoma 10.9 KRT20 KRT7
23 transverse colon cancer 10.9 KRT20 KRT7
24 appendix adenocarcinoma 10.9 KRT20 KRT7
25 eyelid neoplasm 10.9 KRT20 KRT7
26 mixed type thymoma 10.9 KIT SYP
27 glandular cystitis 10.9 KRT20 KRT7
28 mucinous adenofibroma 10.9 KRT7 SYP
29 reticular perineurioma 10.9 KIT MUC1
30 malignant syringoma 10.9 KRT20 KRT7
31 pilomatrix carcinoma 10.9 ENO2 MUC1
32 krukenberg carcinoma 10.9 KRT20 KRT7
33 large intestine adenocarcinoma 10.9 KRT20 KRT7
34 linitis plastica 10.9 KRT20 KRT7
35 intracranial cysts 10.9 ENO2 MUC1
36 ovarian germ cell teratoma 10.9 KRT7 NKX2-1
37 adenoid squamous cell carcinoma 10.9 KRT20 KRT7
38 jejunal cancer 10.9 KIT KRT7
39 subependymal glioma 10.8 ENO2 SYP
40 ovarian germ cell cancer 10.8 KRT7 NKX2-1
41 lung combined type small cell carcinoma 10.8 NCAM1 SYP
42 bladder papillary transitional cell neoplasm 10.8 KRT20 TP53
43 urinary tract papillary transitional cell benign neoplasm 10.8 KRT20 TP53
44 multiple mucosal neuroma 10.8 ENO2 NCAM1
45 clear cell meningioma 10.8 CHGA MUC1
46 microcystic adenoma 10.8 ENO2 MUC1
47 gastric leiomyosarcoma 10.8 ENO2 KIT
48 ossifying fibromyxoid tumor 10.8 ENO2 MUC1
49 papillary adenoma 10.8 KRT7 NKX2-1
50 prostatic acinar adenocarcinoma 10.8 KIT KRT20

Graphical network of the top 20 diseases related to Merkel Cell Carcinoma:



Diseases related to Merkel Cell Carcinoma

Symptoms & Phenotypes for Merkel Cell Carcinoma

Human phenotypes related to Merkel Cell Carcinoma:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 merkel cell skin cancer 59 32 obligate (100%) Obligate (100%) HP:0030447
2 cutaneous photosensitivity 59 32 frequent (33%) Frequent (79-30%) HP:0000992
3 chronic noninfectious lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002730
4 cellular immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0005374
5 regional abnormality of skin 59 32 frequent (33%) Frequent (79-30%) HP:0011356
6 erythematous plaque 59 32 frequent (33%) Frequent (79-30%) HP:0025474
7 erythematous macule 59 32 frequent (33%) Frequent (79-30%) HP:0025475
8 skin nodule 59 32 frequent (33%) Frequent (79-30%) HP:0200036
9 basal cell carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002671
10 lymphoid leukemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0005526
11 squamous cell carcinoma of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0006739
12 multiple myeloma 59 32 occasional (7.5%) Occasional (29-5%) HP:0006775
13 carcinoid tumor 59 32 occasional (7.5%) Occasional (29-5%) HP:0100570
14 abnormal brain fdg positron emission tomography 59 32 very rare (1%) Very rare (<4-1%) HP:0012658
15 brain neoplasm 59 32 very rare (1%) Very rare (<4-1%) HP:0030692
16 neoplasm of the outer ear 59 32 very rare (1%) Very rare (<4-1%) HP:0040095
17 pain 59 Excluded (0%)

MGI Mouse Phenotypes related to Merkel Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 KIT MAP2 NCAM1 NKX2-1 PAX5 ATOH1
2 mortality/aging MP:0010768 9.9 KIT KRT8 MAP2 NCAM1 NKX2-1 PAX5
3 nervous system MP:0003631 9.65 KIT MAP2 NCAM1 NKX2-1 PAX5 ATOH1
4 no phenotypic analysis MP:0003012 9.17 KIT NKX2-1 ATOH1 SST CD274 CHGA

Drugs & Therapeutics for Merkel Cell Carcinoma

Drugs for Merkel Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 3,Phase 2,Phase 1
2 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
3 Immunoglobulins Phase 3,Phase 2,Phase 1
4
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
6
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
7 lanreotide Approved Phase 2 108736-35-2
8
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
9
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
10
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
11
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
12
nivolumab Approved Phase 2,Phase 1 946414-94-4
13
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
14
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
15
Daratumumab Approved Phase 1, Phase 2 945721-28-8
16
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
17
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
18
Etoposide Approved Phase 2 33419-42-0 36462
19
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
20
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
21
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
24
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
25
Serine Approved, Nutraceutical Phase 1, Phase 2 56-45-1 5951
26
Camptothecin Experimental Phase 2 7689-03-4
27
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
28 Adjuvants, Immunologic Phase 2
29 Angiogenesis Inhibitors Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 2,Phase 1
31 Interleukin-12 Phase 2
32 Vaccines Phase 2,Phase 1
33 Alkylating Agents Phase 2,Phase 1
34 Antimetabolites Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 2,Phase 1
36 Antineoplastic Agents, Alkylating Phase 2,Phase 1
37 Antirheumatic Agents Phase 2,Phase 1
38 Dermatologic Agents Phase 2
39 Folic Acid Antagonists Phase 2
40 Immunosuppressive Agents Phase 2,Phase 1
41 Nucleic Acid Synthesis Inhibitors Phase 2
42 Vitamin B Complex Phase 2
43 Imatinib Mesylate Phase 2 220127-57-1 123596
44 Protein Kinase Inhibitors Phase 2,Phase 1
45 Angiopeptin Phase 2
46 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
47 topoisomerase I inhibitors Phase 2
48 Topoisomerase Inhibitors Phase 2
49 Anti-Infective Agents Phase 1, Phase 2,Phase 2
50 Gastrointestinal Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Adjuvant Avelumab in Merkel Cell Cancer Recruiting NCT03271372 Phase 3 Avelumab
2 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Completed NCT01440816 Phase 2
3 S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
4 Oblimersen in Treating Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
5 S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Completed NCT00068783 Phase 2 imatinib mesylate
6 Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Completed NCT02351128 Phase 2 Lanreotide
7 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
8 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
9 Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation Recruiting NCT02196961 Phase 2 Ipilimumab;Nivolumab
10 Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Recruiting NCT02584829 Phase 1, Phase 2 Avelumab
11 Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Recruiting NCT03071406 Phase 2 Nivolumab;Ipilimumab
12 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting NCT02819843 Phase 2 TALIMOGENE LAHERPAREPVEC (TVEC)
13 Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Recruiting NCT03304639 Phase 2
14 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
15 Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Recruiting NCT03322384 Phase 1, Phase 2 epacadostat;SD-101
16 Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1 Recruiting NCT03390296 Phase 2 PF-04518600;Avelumab;Azacitidine;Utomilumab;Gemtuzumab Ozogamicin;Glasdegib
17 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
18 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting NCT03435640 Phase 1, Phase 2 NKTR-262;NKTR-214;nivolumab
19 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
20 A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03241173 Phase 1, Phase 2 INCAGN01949;Nivolumab;Ipilimumab;INCAGN01949
21 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03126110 Phase 1, Phase 2 INCAGN01876;Nivolumab;Ipilimumab
22 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
23 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02514824 Phase 1, Phase 2 MLN0128
24 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02036476 Phase 2 Cabozantinib
25 QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Active, not recruiting NCT02465957 Phase 2
26 Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Active, not recruiting NCT02155647 Phase 2 Avelumab
27 Merkel Positron Emission Tomography (PET) Protocol Active, not recruiting NCT01013779 Phase 2 Carboplatin;Etoposide
28 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Active, not recruiting NCT02267603 Phase 2
29 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma Active, not recruiting NCT02501473 Phase 1, Phase 2 G100;Pembrolizumab
30 INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Active, not recruiting NCT03277352 Phase 1, Phase 2 INCAGN01876;Epacadostat;Pembrolizumab
31 QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Not yet recruiting NCT03167164 Phase 1, Phase 2 Capecitabine;Cisplatin;Cyclophosphamide;5-fluorouracil;Leucovorin;nab-Paclitaxel;omega-3-acid ethyl esters
32 F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Terminated NCT02054884 Phase 2 Arm A: F16IL2 in combination with paclitaxel;Arm B: Paclitaxel
33 Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Terminated NCT01758458 Phase 1, Phase 2
34 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2 Ipilimumab
35 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
36 A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Completed NCT02035657 Phase 1
37 A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel C Completed NCT01652547 Phase 1 Pasireotide sub-cutaneous formulation;Pasireotide lon acting release formulation
38 BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00346385 Phase 1 BB-10901
39 Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System Completed NCT01172860 Phase 1
40 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
41 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
42 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
43 ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma Recruiting NCT03107663 Phase 1 ⁸⁹Zr-Df-IAB22M2C Infusion
44 T-VEC in Non-melanoma Skin Cancer Recruiting NCT03458117 Phase 1
45 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Recruiting NCT02890368 Phase 1 TTI-621 Monotherapy;TTI-621 + PD-1/PD-L1 Inhibitor;TTI-621 + pegylated interferon-α2a
46 Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers Recruiting NCT03212404 Phase 1 CK-301
47 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03071757 Phase 1 ABBV-368;Nivolumab
48 A Study of ABBV-181 in Participants With Advanced Solid Tumors Recruiting NCT03000257 Phase 1 Rovalpituzumab Tesirine;ABBV-181
49 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Not yet recruiting NCT03538028 Phase 1
50 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1

Search NIH Clinical Center for Merkel Cell Carcinoma

Genetic Tests for Merkel Cell Carcinoma

Anatomical Context for Merkel Cell Carcinoma

MalaCards organs/tissues related to Merkel Cell Carcinoma:

41
Skin, Lymph Node, Brain, T Cells, Pancreas, Thyroid, Myeloid

Publications for Merkel Cell Carcinoma

Articles related to Merkel Cell Carcinoma:

(show top 50) (show all 832)
# Title Authors Year
1
A 21-year course of Merkel cell carcinoma with adjuvant Viscum album extract treatment: A case report. ( 29857880 )
2018
2
MicroRNAs as Potential Biomarkers in Merkel Cell Carcinoma. ( 29949882 )
2018
3
Merkel Cell Carcinoma in a Steer. ( 29422311 )
2018
4
Radiotherapy in the Multidisciplinary Management of Merkel Cell Carcinoma. ( 29891527 )
2018
5
Radiation Therapy Rather Than Surgery for Merkel Cell Carcinoma: The Advantages of Radiation Therapy. ( 29254767 )
2018
6
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
7
Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. ( 29445030 )
2018
8
Merkel cell carcinoma: a single-institution retrospective case series analyzing CD271 expression with a focus on its prognostic role. ( 29963808 )
2018
9
Incidental Merkel Cell Carcinoma Encountered During Mohs Surgery. ( 29933296 )
2018
10
Adjuvant radiation therapy improves patient survival in early-stage merkel cell carcinoma: A 15-year single-institution study. ( 29314048 )
2018
11
Merkel cell polyomavirus Integration-PCR in bilateral metachronous Merkel cell carcinoma on the nose. ( 29888815 )
2018
12
Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity. ( 29808366 )
2018
13
How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. ( 29914528 )
2018
14
Avelumab: A Review in Metastatic Merkel Cell Carcinoma. ( 29799096 )
2018
15
Systematic review of sentinel lymph node biopsy in Merkel cell carcinoma of the head and neck. ( 29934958 )
2018
16
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. ( 29891526 )
2018
17
A Monoclonal Antibody to SV40 Large T Antigen (PAb416) Does Not Label Merkel Cell Carcinoma. ( 29430700 )
2018
18
Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide. ( 29891528 )
2018
19
Are there multiple cells of origin of Merkel cell carcinoma? ( 29321666 )
2018
20
Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. ( 29913261 )
2018
21
Merkel cell carcinoma in France: A registries-based, comprehensive epidemiological survey. ( 29341266 )
2018
22
Retrospective study on the correlation between 18-fluorodeoxyglucose uptake in positron emission tomography-computer tomography and tumour volume, cytological activity as assessed with Ki-67 and GLUT-1 staining in 10 cases of Merkel cell carcinoma. ( 29377285 )
2018
23
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after a8Y1A year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. ( 29347993 )
2018
24
Outcome of Combined Treatment of Surgery and Adjuvant Radio-therapy in Merkel Cell Carcinoma. ( 29379978 )
2018
25
Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature. ( 29894357 )
2018
26
Primary Radiation Therapy for Merkel Cell Carcinoma. ( 29254768 )
2018
27
Merkel cell carcinoma with intramedullary spinal cord metastasis: a very rare clinical finding. ( 29881592 )
2018
28
Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors? ( 29933728 )
2018
29
Investigation of the Diagnostic Precision and Utility of Sentinel Lymph Node Biopsy in the Treatment of Patients with Merkel Cell Carcinoma. ( 29966556 )
2018
30
Influence of age and marital status on stage at diagnosis and survival of patients with Merkel cell carcinoma: a SEER based cohort study. ( 29864470 )
2018
31
Merkel Cell Carcinoma in a Patient With CLL/Atypical AML. ( 29865947 )
2018
32
The Touchy Topic of the Touch Cell: A Case of Merkel Cell Carcinoma. ( 29254766 )
2018
33
New and emerging treatments for metastatic Merkel Cell Carcinoma. ( 29332376 )
2018
34
Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. ( 29405630 )
2018
35
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. ( 29848371 )
2018
36
Merkel Cell Carcinoma of the Cheek. ( 29419589 )
2018
37
Demographics and Outcomes of Stage I-II Merkel Cell Carcinoma Treated with Mohs Micrographic Surgery Compared with Wide Local Excision in the National Cancer Data Base. ( 29408552 )
2018
38
Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment. ( 28762116 )
2017
39
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. ( 28950303 )
2017
40
MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo. ( 28405827 )
2017
41
Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor. ( 29265481 )
2017
42
Skin ultrasound features of Merkel cell carcinoma. ( 28045198 )
2017
43
Merkel Cell Carcinoma. ( 28920480 )
2017
44
Update on Merkel Cell Carcinoma. ( 28802497 )
2017
45
Expression of Merkelcell polyomavirus (MCPyV) large T-antigen in Merkel cell carcinoma lymph node metastases predicts poor outcome. ( 28763479 )
2017
46
Merkel cell carcinoma: Do Australians have a more aggressive variant and a worse outcome? ( 28804895 )
2017
47
Association of expression of the hedgehog signal with Merkel cell polyomavirus infection and prognosis of Merkel cell carcinoma. ( 28551328 )
2017
48
Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells. ( 28793172 )
2017
49
Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab. ( 28761962 )
2017
50
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. ( 28049147 )
2017

Variations for Merkel Cell Carcinoma

ClinVar genetic disease variations for Merkel Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.1412C> T (p.Pro471Leu) single nucleotide variant not provided rs1057519872 GRCh37 Chromosome 3, 178928226: 178928226
2 PIK3CA NM_006218.3(PIK3CA): c.1412C> T (p.Pro471Leu) single nucleotide variant not provided rs1057519872 GRCh38 Chromosome 3, 179210438: 179210438

Cosmic variations for Merkel Cell Carcinoma:

9
(show top 50) (show all 696)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6932965 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.6172C>T p.P2058S 16:72796510-72796510 19
2 COSM6949138 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.10363C>T p.P3455S 16:72787913-72787913 19
3 COSM6963354 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.6661G>A p.E2221K 16:72796021-72796021 19
4 COSM6935975 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.380C>T p.S127F 11:102114202-102114202 19
5 COSM6912621 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.630G>C p.M210I 11:102162513-102162513 19
6 COSM6917521 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.371G>C p.R124P 11:102114193-102114193 19
7 COSM6932922 VEGFA skin,NS,carcinoma,Merkel cell carcinoma c.855+1G>T p.? 6:43777666-43777666 19
8 COSM6947750 VEGFA skin,NS,carcinoma,Merkel cell carcinoma c.983G>A p.G328E 6:43780752-43780752 19
9 COSM6917817 TSHR skin,NS,carcinoma,Merkel cell carcinoma c.1105G>A p.E369K 14:81143163-81143163 19
10 COSM6917819 TSC2 skin,NS,carcinoma,Merkel cell carcinoma c.2519C>T p.A840V 16:2074363-2074363 19
11 COSM6505726 TSC2 skin,NS,carcinoma,Merkel cell carcinoma c.5213C>T p.S1738F 16:2088279-2088279 19
12 COSM6927263 TSC1 skin,NS,carcinoma,Merkel cell carcinoma c.2204C>T p.A735V 9:132903655-132903655 19
13 COSM6917821 TRAF7 skin,NS,carcinoma,Merkel cell carcinoma c.1871C>T p.S624F 16:2176173-2176173 19
14 COSM6932958 TRAF7 skin,NS,carcinoma,Merkel cell carcinoma c.1601A>T p.Y534F 16:2175597-2175597 19
15 COSM11166 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 19
16 COSM10863 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.833C>T p.P278L 17:7673787-7673787 19
17 COSM10939 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.832C>T p.P278S 17:7673788-7673788 19
18 COSM45167 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.402T>A p.F134L 17:7675210-7675210 19
19 COSM78687 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.313G>A p.G105S 17:7676056-7676056 19
20 COSM6920904 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.767C>G p.T256R 17:7674196-7674196 19
21 COSM10794 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.796G>A p.G266R 17:7673824-7673824 19
22 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 17:7674221-7674221 19
23 COSM44140 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.596G>T p.G199V 17:7674935-7674935 19
24 COSM11073 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 19
25 COSM10654 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.637C>T p.R213* 17:7674894-7674894 19
26 COSM43681 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.647T>G p.V216G 17:7674884-7674884 19
27 COSM10726 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.856G>A p.E286K 17:7673764-7673764 19
28 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 17:7673802-7673802 19
29 COSM10705 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.586C>T p.R196* 17:7674945-7674945 19
30 COSM11966 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.485T>A p.I162N 17:7675127-7675127 19
31 COSM45114 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 19
32 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 17:7674220-7674220 19
33 COSM6947754 TOP1 skin,NS,carcinoma,Merkel cell carcinoma c.763G>A p.E255K 20:41097252-41097252 19
34 COSM6914877 TNFAIP3 skin,NS,carcinoma,Merkel cell carcinoma c.826G>A p.V276I 6:137877096-137877096 19
35 COSM6963332 TCF7L2 skin,NS,carcinoma,Merkel cell carcinoma c.472G>A p.A158T 10:113040115-113040115 19
36 COSM6963336 TCF7L2 skin,NS,carcinoma,Merkel cell carcinoma c.1147G>A p.E383K 10:113152387-113152387 19
37 COSM6949151 TCF3 skin,NS,carcinoma,Merkel cell carcinoma c.862C>T p.P288S 19:1621931-1621931 19
38 COSM5196199 TBX3 skin,NS,carcinoma,Merkel cell carcinoma c.400C>T p.P134S 12:114681136-114681136 19
39 COSM6936004 SUFU skin,NS,carcinoma,Merkel cell carcinoma c.3G>A p.M1I 10:102504155-102504155 19
40 COSM6917784 STK40 skin,NS,carcinoma,Merkel cell carcinoma c.115C>T p.P39S 1:36358820-36358820 19
41 COSM4730609 STK40 skin,NS,carcinoma,Merkel cell carcinoma c.1120G>A p.E374K 1:36341943-36341943 19
42 COSM4730611 STK40 skin,NS,carcinoma,Merkel cell carcinoma c.1120G>A p.E374K 1:36341943-36341943 19
43 COSM6917786 STK40 skin,NS,carcinoma,Merkel cell carcinoma c.115C>T p.P39S 1:36358820-36358820 19
44 COSM6974546 STK11 skin,NS,carcinoma,Merkel cell carcinoma c.896C>T p.S299F 19:1221982-1221982 19
45 COSM5386387 STAT5B skin,NS,carcinoma,Merkel cell carcinoma c.2125C>T p.P709S 17:42202761-42202761 19
46 COSM211038 STAG2 skin,NS,carcinoma,Merkel cell carcinoma c.3034C>T p.R1012* 23:124083530-124083530 19
47 COSM6920910 STAG2 skin,NS,carcinoma,Merkel cell carcinoma c.478C>T p.P160S 23:124045179-124045179 19
48 COSM2760683 SRC skin,NS,carcinoma,Merkel cell carcinoma c.487C>T p.R163W 20:37394211-37394211 19
49 COSM6932966 SPOP skin,NS,carcinoma,Merkel cell carcinoma c.229G>A p.D77N 17:49619357-49619357 19
50 COSM6920908 SPOP skin,NS,carcinoma,Merkel cell carcinoma c.837+1G>T p.? 17:49607249-49607249 19

Copy number variations for Merkel Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32219 1 34600000 44100000 Amplification MYCL1 Merkel cell carcinoma
2 77110 13 40100000 73300000 Deletion Merkel cell carcinoma
3 200959 5 63200000 102800000 Deletion Merkel cell carcinoma

Expression for Merkel Cell Carcinoma

Search GEO for disease gene expression data for Merkel Cell Carcinoma.

Pathways for Merkel Cell Carcinoma

Pathways related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.07 CD274 KIT NCAM1 PAX5
2 11.95 KRT20 KRT7 KRT8 MUC1
3 11.56 ENO2 MAP2 NCAM1 NKX2-1 SYP
4 11.03 MAP2 NCAM1 SYP

GO Terms for Merkel Cell Carcinoma

Biological processes related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 9.5 KRT20 KRT7 KRT8
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
3 mast cell degranulation GO:0043303 9.16 CHGA KIT
4 mast cell chemotaxis GO:0002551 8.96 CHGA KIT
5 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Sources for Merkel Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....